# (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

> **NCT03465722** · PHASE3 · COMPLETED · sponsor: **Blueprint Medicines Corporation** · enrollment: 476 (actual)

## Conditions studied

- GIST

## Interventions

- **DRUG:** avapritinib
- **DRUG:** regorafenib

## Key facts

- **NCT ID:** NCT03465722
- **Lead sponsor:** Blueprint Medicines Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-26
- **Primary completion:** 2020-03-09
- **Final completion:** 2021-09-15
- **Target enrollment:** 476 (ACTUAL)
- **Last updated:** 2022-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03465722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03465722, "(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03465722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*